Biotech

All Articles

Merck quits phase 3 TIGIT test in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT plan has experienced an additional misfortune. Months after shuttering a sta...

After a hard year, Exscientia folds right into Recursion

.After a year determined by pipe cuts, the shift of its chief executive officer and cutbacks, Exscie...

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Rehab was actually blown away enough with Port BioMed's bispecific immune reactor that it ...

A deeper take a look at Ferocious Biotech's Strong 15

.In this full week's episode of "The Best Line," our experts are actually diving into Intense Biotec...

Lilly encounters phase 2 breakdown of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's gathering celebrating the approval of Alzheim...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial management hirings, firings a...

Lykos will definitely talk to FDA to rethink its own decision adhering to rejection of MDMA therapy for trauma

.Following an unsatisfactory showing for Lykos Therapies' MDMA candidate for trauma at a latest FDA ...

AN 2 halves headcount, ceases phase 3 trial after data dissatisfy

.AN2 Therapeutics is reconsidering its organization in action to uninspired midphase records, promis...

Merck pays for $700M for bispecific, snooping autoimmune position and chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying for $700 million in advance to test Amgen in a blood cancer cells...

Gilead pays out J&ampJ $320M to leave licensing bargain for seladelpar

.Along With Gilead Sciences almost an FDA selection for its liver disease medication seladelpar, the...